Astrana Health Inc.: stock overview

ASTHNASDAQIndustrials · Services-Management Consulting Services

Price

$31.80

November 13, 2026Market cap $1.8B

DCF calculator

What Ploutos Investor adds for Astrana Health

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 15 fiscal years, from FY2011
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • Earnings per share here are the last twelve months' earnings over today's shares, so they agree with the P/E. The number of shares changed a lot during the year, so they differ from the earnings per share the company filed, which use the year's average number of shares.

In short

Astrana Health had revenue of $3.9B over the last 12 months and net income of $53M, a net margin of 1.4%. Revenue grew by 35.9% a year on average over the last 5 years. At $31.80 the shares trade at a P/E of 33.3, against a median of 35.0 over the last 5 fiscal years. It has net debt of $529M. It pays a dividend yielding 0.09%.

From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 13, 2026.

Its SEC filings
Market cap
$1.8B
55.60M shares
P/E
33.3
Today33.3
Median35.0
Revenue, 12 months
$3.9B
+35.9% a year over 5 years
Net margin
1.4%
2025: 0.8%, above 30% of its industry

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

2023–2025 fiscal years

+51.5% a year over 2 years

  • 202510-K
    Revenue$3.2B
  • 202410-K
    Revenue$2.0B
  • 202310-K
    Revenue$1.4B

Fiscal years in figures

ASTH's revenue, profit, cash flow and dividend with each year-end price, from FY2011 to 2022, 12 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $1.8B
$1.8B
Enterprise value 
$2.3B
P/E 3-year median: 35.0
33.3
EV / EBIT 
19.0
EV / Revenue 
0.6
P/B 3-year median: 2.5
2.1
FCF yield 3-year median: 2.5%
5.6%
Earnings yield 3-year median: 2.9%
3.0%

Profitability

Gross margin 
11.0%
Operating margin 
3.1%
Net margin 3-year median: 2.1%
1.4%
ROIC 
4.5%
ROIC, 5-year average 
8.1%
ROE 
6.6%

Growth

Revenue, yearly change 
+56.4%
EPS, yearly change 
-48.9%
FCF, yearly change 
+136.6%
Revenue, average a year 
+35.9%
EPS, average a year 
-14.5%

The yearly change compares FY2025 with FY2024.

Balance sheet

Cash 
$396M
Total debt 
$977M
Of which operating leases 
$52M
Net debt 
$529M
Net debt / EBITDA 
3.2x
Interest cover 
1.9x
Current ratio 
1.25

Balance sheet of September 30, 2026.

Returns to shareholders

Dividend yield 3-year median: 0.6%
0.09%
Buybacks 
1.45%
Total returned 
1.54%
Shares, yearly change 
-1.2%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

Against its industry

Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 87).

Operating margin

2.5%

Above 31% of the 43 companies in its industry, and 42% of all.

Net margin

0.8%

Above 30% of the 42 companies in its industry, and 37% of all.

ROE

3.1%

Above 37% of the 39 companies in its industry, and 38% of all.

ROA

1.1%

Above 33% of the 41 companies in its industry, and 45% of all.

Revenue growth

56.4%

Above 96% of the 40 companies in its industry, and 95% of all.

From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
Astrana Health, Inc.
CIK
1083446
Exchange
NASDAQ
Industry (SIC)
8742 · Services-Management Consulting Services
Fiscal year ends
December 31
Latest annual report
December 31, 2025
Reporting currency
USD
Shares
55.60M

Other companies: Industrials

The largest companies of the same sector, each with its own page.

The Industrials sectorAll companies

The full analysis

What do Astrana Health's filings show?

These are Astrana Health's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about ASTH

Didn't find what you were looking for?

Ask us
What is ASTH's market cap?

Astrana Health Inc.'s market cap is $1.8B, at a price of $31.80 on November 13, 2026 and 55.60M shares.

What is ASTH's P/E?

ASTH's P/E is 33.3, on earnings per share of $0.96 over the last 12 months. The median over the last 5 fiscal years was 35.0.

How much revenue does ASTH have?

Astrana Health had revenue of $3.9B over the last 12 months. Over the last 5 years it changed by +35.9% a year on average.

Does ASTH pay a dividend?

Yes. Astrana Health paid $0.03 per share over the last 12 months, a yield of 0.09% at today's price. All the figures are in the Dividend section.

Where do the figures come from?

From Astrana Health Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.